US OTC: AIRDF | CSE: AIDR
This page is disseminated by 45 Degrees on behalf of Rocket Doctor AI
US OTC: $AIRDF | Canada: $AIDR
The Quietly Emerging ~$50M USD Healthcare AI Company Gaining Ground on $1B+ Industry Giants
Rocket Doctor AI reports 89% gross margin on Rocket Doctor’s Q2 earnings, marking transformation
from a pre-revenue AI company to an organization generating revenue. While healthcare AI unicorns command
billion-dollar valuations with minimal revenue, Rocket Doctor AI currently trades at a ~$40M USD market cap
despite having innovative AI technology, proven revenue, and an announced pipeline of Medicaid contracts
covering millions of underserved patients.
US OTC: $AIRDF | Canada: $AIDR
The Quietly Emerging ~$50M USD Healthcare AI Company Gaining Ground on $1B+ Industry Giants
Rocket Doctor AI reports 89% gross margin on Rocket Doctor’s Q2 earnings, marking transformation from a pre-revenue AI company to an organization generating revenue. While healthcare AI unicorns command billion-dollar valuations with minimal revenue, Rocket Doctor AI currently trades at a ~$40M USD market cap despite having innovative AI technology, proven revenue, and an announced pipeline of Medicaid contracts covering millions of underserved patients.
The Revenue Inflection Is Here
For the first time in Rocket Doctor AI’s history, their Q2 2025 financials are expected to show consolidated revenues following the April acquisition of Rocket Doctor – a technology-driven digital health platform and marketplace serving 600,000+ patients across 4 provinces and 3 U.S. states. This isn’t theoretical anymore. Rocket Doctor AI has announced:
- Future projected additional $1.2M USD ARR from California Managed Care Plan alone, with an anticipated GM of $18/visit across some 45,000 visits in Year 1
- 600,000+ patients and 300+ physicians on the platform
- CVS Health Foundation funding a 5 year, $1M grant to support older adults
The market hasn’t noticed yet because Rocket Doctor AI has been quietly building. That’s about to change.
The Medicaid Gold Mine Others Are Ignoring
Here’s what makes Rocket Doctor AI’s strategy brilliant: one of its targets is the 71.3 million Americans on Medicaid– a massive, underserved population that other AI healthcare companies avoid because of “lower margins.”
But Rocket Doctor AI’s unit economics tell a different story:
- Medicaid patients pay $0 to see doctors (fully covered)
- Treatment can earn $18 per visit
- Chronic disease patients require multiple visits annually (between 6 and 10)
- Limited customer acquisition battles with well-funded competitors
New revenues will also ensue from Rocket Doctor being announced as an In Network provider for New York Medicaid approval covering 6.9M Medicaid beneficiaries (enabling affordable medical care accessibility for ~ 35% of New York’s population).
Tested Proprietary AI Technology but an Inferior Valuation
Rocket Doctor AI’s Global Library of Medicine (GLM) represents 9 years of physician-curated medical knowledge – not the probabilistic guesswork of large language models. Key differentiators include:
Emphasis on Clinical Accuracy
A non-medical undergraduate used Rocket Doctor AI’s system to correctly diagnose 11 of 12 patients in a medical school-level clinical exam (OSCE)—a 92% success rate that demonstrates the platform’s diagnostic precision. (A typical passing score is anywhere from 60-70%)
Curated vs. Generative AI
While competitors like OpenEvidence ($3.5B valuation) rely on research papers (many of which are later proven false), Rocket Doctor AI’s GLM uses:
- Inputs from hundreds of doctors globally, since 2016
- 10,000+ expert medical reviews
- 1,000+ diseases and 17,000+ symptoms
- 2nd and 3rd pass technology to enhance the accuracy of diagnostic recommendations (The platform will suggest which labs and imaging the patient should go for and when the results come back, it dynamically adjusts the differential diagnosis in real time based on the new data)
- Physician-validated diagnostic logic
- Audit trails for every recommendation
Multiple Deployment Options
The GLM can be consumed in multiple ways, including powering chatbots, voice assistants, and avatars—all can be white-labeled and multilingual. Rocket Doctor AI has designed its platform to integrate with electronic medical records (EMRs), telehealth platforms, or health systems and can reside behind a client firewall for security.
The Valuation Disconnect seems Evident??
Rocket Doctor AI acquired the digital health platform and marketplace for a max payout of $14.6M. It could be perceived that investors today are essentially getting the proprietary GLM AI technology for free.
Why the Market Missed This Story
Rocket Doctor AI’s journey illustrates a classic venture capital irony: the company with proprietary AI technology and a clear revenue path is trading at a fraction of pre-revenue competitors’ valuations.
The reasons are structural:
- Public vs. Private: Rocket Doctor AI trades on the Canadian Securities Exchange, not in Silicon Valley boardrooms
- Timing: The revenue story only emerged with the Rocket Doctor acquisition
- Market Awareness: No institutional coverage despite superior fundamentals
As one insider noted: “We’re trading on an overlooked exchange while inferior products get billion-dollar valuations from the right investors.”
Multiple Catalysts Ahead
Immediate (Q3 2025)
- Q2 earnings release showing first consolidated revenue
- Medicaid contract pipeline progression across multiple states
Medium-term (Q4 2025 – Q1 2026)
- Initial GLM licensing deals
- Potential expansion to additional states
Longer-term (2026+)
- Prospective NASDAQ uplisting (target: $100M+ market cap)
- Enterprise GLM deployments across health systems
- International expansion through announced partnerships
The Investment Case
Revenue Validation
Rocket Doctor AI isn’t another AI story seeking product-market fit. They have:
- Contracted revenue from government Medicaid programs
- Proven demand from 600K+ patients and 300+ physicians
- Award-winning platform recognized at medical conferences
Scalable Technology
The GLM represents a 9-year head start in medical AI that competitors can’t replicate quickly. It’s designed to be:
- Clinically validated by physicians
- Regulatory-ready with full audit trails
- Platform-agnostic for multiple deployment scenarios
- Defensible through physician network effects
Market Timing
Healthcare AI is the hottest sector in venture capital, with $3.95B invested in H1 2025 alone. Treatment offers:
- Public market access to private-market-quality AI technology
- Revenue traction that most AI unicorns lack
- Undervalued entry point before institutional discovery
Risks to Consider
Execution Risk
Scaling patient acquisition across multiple states requires operational excellence and regulatory navigation.
Competition Risk
Well-funded competitors may eventually target the Medicaid market, though Rocket Doctor AI’s head start and relationships provide protection.
Market Risk
Healthcare AI valuations could compress, though Rocket Doctor AI’s revenue base provides downside protection that pre-revenue competitors lack.
The Bottom Line
Rocket Doctor AI represents a rare opportunity: a revenue-generating AI healthcare platform trading at a fraction of comparable valuations. The company has:
✅ Proprietary and Accurate technology (physician-curated vs. probabilistic AI)
✅ Contracted and emerging revenue streams ($1.38M+ USD ARR potential, with initial revenues already recognized)
✅ A massive addressable market (71.3M Medicaid patients)
✅ Multiple growth catalysts through managed care and specialty service expansion
While many healthcare AI unicorns capture headlines with billion-dollar valuations and minimal revenue, Rocket Doctor AI has quietly built a proprietary platform, validated by clinicians, to serve millions of underserved patients with technology that actually works.
The Q2 earnings release will mark Rocket Doctor AI’s coming-out party. For investors seeking AI exposure with real revenue validation, this may be the last chance to get in before broader institutional discovery.
Investment Highlights
- Market Cap: ~$24M USD
- Revenue: $1.38M USD + ARR (second quarter reporting in August)
- Addressable Market: 73M U.S. Medicaid patients
- Competitive Moat: 9-year physician-curated medical AI database
Investor Overview
Request our investor pack
Disclaimer
45 Degrees, Inc (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Rocket Doctor AI will make a one-time payment of $180,000 USD and 400,000 options at .45 CAD to provide marketing services for a term of 6 months. We or certain non-arms length parties own 30000 common shares of Rocket Doctor AI. This article is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.
Forward Looking Statements
This article contains forward-looking statements about Treatment.com AI Inc., which are identified by terms such as “anticipate,” “expect,” and “project.” These statements reflect current views regarding company performance, business goals, healthcare market expectations, and intellectual property development. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article’s publication date and we undertake no obligation to update.
Contact Us
45 Degrees, Inc
1601 Central Ave Cheyenne, WY 82001
Phone +1.672.906.227
email:
info@45degrees.media
Copyright 2025. 45 Degrees, Inc.. All Rights Reserved.